TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01565681
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion
Study: NCT00589771
Drug: Saccharomyces boulardii
Normalized name: Saccharomyces boulardii
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Saccharomyces boulardii one capsule 250mg TDS for 6 weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks
Study: NCT00589771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Cap Placebo TDS for six weeks~2. Ispaghula husk 1 Tsf daily after dinner for six weeks
Study: NCT00776711
Drug: Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01729156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets twice daily in 3 months
Study: NCT04082715
Drug: carbidopa/levodopa and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patient of this arm will get one bottle of carbidopa/levodopa and one bottle of celecoxib. At treatment initiation, Carbidopa/Levodopa will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with carbidopa/levodopa twice daily for 3 days and then once daily for 3 days before discontinuing it completely.Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
Study: NCT04082715
Drug: placebo1 and celecoxib
Normalized name: amlodipine and celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patient of this arm will get one bottle of placebo1 and one bottle of celecoxib. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. Celecoxib will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
Study: NCT04082715
Drug: placebo1 and placebo2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patient of this arm will get one bottle of placebo1 and one bottle of placebo2. At treatment initiation, placebo1 will be taken once daily for 3 days, then twice daily for 3 days, and then thrice daily over one week and then continue on that dose for the duration of the treatment period (12 weeks total). At the last treatment visit (end of the treatment period), patients will begin tapering off the medication as follows. S/he will start with placebo1 twice daily for 3 days and then once daily for 3 days before discontinuing it completely. placebo2 will remain constant once daily for patients of this arm throughout the treatment period, but it will not be given during the tapering down at the end of the treatment period(12 weeks total).
Study: NCT01726582
Drug: Milestone 1: Targeted chemotherapy prior to surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
Study: NCT01726582
Drug: Milestone 3: Targeted chemotherapy prior to surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
Study: NCT01726582
Drug: Milestone 4: standard FOLFIRINOX chemotherapy prior to surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
Study: NCT01726582
Drug: Milestone 5: Targeted chemotherapy after surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
Study: NCT01726582
Drug: Milestone 8: Targeted chemotherapy after surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
Study: NCT01247168
Drug: AZD2461
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules, continuous dosing and intermittent dosing
Study: NCT00551109
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, oral administration, once daily for 8 weeks
Study: NCT02057172
Drug: HM11260C
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Study: NCT02057172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03329092
Drug: ATM-AVI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI~(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI
Study: NCT04412772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1 dose of IV placebo matched to TCZ. Up to 1 additional dose may be given if clinical symptoms worsen.
Study: NCT02693613
Drug: ASP1517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02693613
Drug: Kremezin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04426955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT00181584
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given intravenously once.
Study: NCT00783614
Drug: Antiretroviral therapy (ART)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to start ART immediately or defer use for 1 month
Study: NCT02113241
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, 10 mg, one per day before breakfast during 90 days.
Study: NCT01915173
Drug: Supplement
Normalized name: fat supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
Study: NCT03025399
Drug: Tangwang prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
Study: NCT03025399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
Study: NCT01915173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose tablets
Study: NCT00830466
Drug: Laser and rapamycin versus laser alone
Normalized name: ELECTRODE GEL,LASER TOUCH ONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser and rapamycin versus laser alone
Study: NCT00847886
Drug: LX3305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral intake of LX3305 for 14 days.
Study: NCT00847886
Drug: LX3305 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo dosing with daily oral intake for 14 days.
Study: NCT00847886
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Once weekly stable-dose methotrexate.
Study: NCT01517555
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
Study: NCT00345865
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.~HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m\^2 over 2 hours daily x 4 days.~Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing.
Study: NCT03665493
Drug: PD patients H&Y=1.5-2 Medications ON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
Study: NCT03665493
Drug: PD patients H&Y=1.5-2 Medications OFF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
Study: NCT03665493
Drug: PD patients H&Y=3 Medications OFF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parkinson's patients will not take medications overnight prior to the study (20). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients. This intervention will be given on a different day with respect to the Medication ON intervention. The order of intervention will be counterbalanced across subjects
Study: NCT03665493
Drug: PD patients H&Y=3 Medications ON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parkinson's patients will be allowed to the first-morning dose of levodopa medicament (levodopa, dopamine agonists, anticholinergic drugs, or a combination of levodopa and an anticholinergic drug) which normally allowed the patient to attain the best control of symptoms one hour before being tested (19). Patients will perform both the stop-signal task and the go-only task. Experimental conditions will be counterbalanced across patients.
Study: NCT00492895
Drug: Discontinuation of Azathioprin
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discontinuation of Azathioprin
Study: NCT04311567
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Open-label methotrexate for 48 weeks. All subjects (both arms) receive prednisone starting at 20 mg QD with tapering for 6 weeks. Patients with incomplete response at 24 weeks will escalate to combination therapy with tofacitinib 5 mg BID + methotrexate 20 mg weekly up to week 48.
Study: NCT00621010
Drug: CTS21166 (ZPQ-21166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.~Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion
Study: NCT01807091
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive outpatient induction chemotherapy
Study: NCT03382262
Drug: FX006 32 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release 32 mg FX006 IA injection
Study: NCT03382262
Drug: TAcs 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release 40mg TAcs IA injection
Study: NCT03641794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03425643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline by IV infusion Q3W, given on cycle day 1.
Study: NCT02916901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04613271
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500 mg once a day for 5 days.
Study: NCT01407406
Drug: BIIB023 - high dose IV Dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01464125
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin capsules 250 mg x 3 twelve-hourly for three days
Study: NCT02502162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT04213924
Drug: 5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 % Lidocaine Topical Gel and 800 mg ibuprofen intravenously, 30 min before the ESWL procedure.
Study: NCT00498134
Drug: Triple therapy for H. pylori infection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00498134
Drug: Cox-2 inhibitor
Normalized name: COX-2 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04376970
Drug: FLUCON®
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug was prescribed monthly according to the predefined regimen. It was not namely specefied in the prescription and was delivered by the hospital pharmacy according to the randomisation list.The subjects were masked to the contents and were instructed to return the empty tubes on monthly visit, wherein 1 pack of topical treatment was provided to them. Neither the patient nor the ophthalmologist knew the allocated treatment. No other medication was allowed during the trial. Duration of the whole regimen was six months. The study included an extra month after the end of the regimen. It was called  wash-out . Patients who had less than one month of treatment or an uncontrolled treatment side effect or who presented a degenerative iron line were excluded from the rest of the regimen.
Study: NCT03793361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets - Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression~Provided by BAYER
Study: NCT03856827
Drug: IW-6463
Approvals — FDA: no, EMA: no, PMDA: no
Description: IW-6463 Tablet
Study: NCT03856827
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Tablet
Study: NCT03523702
Drug: PembroRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients whose tumors are found to have high (≥ 50%) PD-L1 expression will automatically be placed in the PembroRT group. These patients will receive three intravenous treatments with pembrolizumab, followed by four weeks of daily radiotherapy, followed by up to 12 more treatments with pembrolizumab. Pembrolizumab is given as an intravenous infusion once every three weeks. This treatment course will last, in total, up to one year.~Patients whose tumors are found to have low (\< 50%) PD-L1 will be treated with a standard-o-care regimen and not be a part of this clinical trial.
Study: NCT00795236
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
Study: NCT02549001
Drug: P-3058 10%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02549001
Drug: vehicle of P-3058 10%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01413828
Drug: concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
Study: NCT01413828
Drug: sequential
Normalized name: TABLET, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
Study: NCT03372447
Drug: Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular dose of hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg.
Study: NCT01022138
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
Study: NCT01010971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo HFA Nasal Aerosol once daily
Study: NCT02515188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
Study: NCT02500953
Drug: ASP3325
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02500953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04488926
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: (antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
Study: NCT04488926
Drug: Rescue Drug
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use as needed allowed
Study: NCT00812773
Drug: GSK2190915
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product
Study: NCT00653588
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg
Study: NCT04661007
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
Study: NCT02715804
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for PEGPH20
Study: NCT00205946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
Study: NCT04506281
Drug: neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
Study: NCT00626834
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo BID
Study: NCT02550119
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01651871
Drug: S-555739 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00907504
Drug: CP-751,871
Approvals — FDA: no, EMA: no, PMDA: no
Description: CP-751,871 20mg/kg every 3 weeks
Study: NCT03890744
Drug: ModraDoc006/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study: NCT00731679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02683707
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV peri-procedural analgesia
Study: NCT00646425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match basiliximab
Study: NCT00132808
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg intravenous
Study: NCT00132808
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic 0.9% normal saline
Study: NCT03250624
Drug: CD5024 0.3% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.
Study: NCT03250624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.
Study: NCT02218762
Drug: Placebo to Match DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
Study: NCT00585520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00264225
Drug: Lamaline® , 3 different doses, Dafalgan codeine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01325688
Drug: PEP005 (ingenol mebutate) Gel, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
Study: NCT06727357
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: in according to institutional guidelines
Study: NCT01276990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drinking solution
Study: NCT00882882
Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01116310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bottles containing 60 capsules.
Study: NCT01714713
Drug: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1, 2